Compare OWLT & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OWLT | INDP |
|---|---|---|
| Founded | 2013 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 148.4M | 125.2M |
| IPO Year | 2020 | 2021 |
| Metric | OWLT | INDP |
|---|---|---|
| Price | $4.75 | $3.59 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $17.50 | N/A |
| AVG Volume (30 Days) | 216.9K | ★ 1.9M |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $105,708,000.00 | N/A |
| Revenue This Year | $22.81 | N/A |
| Revenue Next Year | $20.45 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 35.43 | N/A |
| 52 Week Low | $4.19 | $0.92 |
| 52 Week High | $16.94 | $8.57 |
| Indicator | OWLT | INDP |
|---|---|---|
| Relative Strength Index (RSI) | 38.41 | 71.94 |
| Support Level | $4.28 | $2.41 |
| Resistance Level | $6.08 | $3.75 |
| Average True Range (ATR) | 0.21 | 0.41 |
| MACD | -0.02 | 0.27 |
| Stochastic Oscillator | 24.36 | 84.48 |
Owlet Inc is engaged in providing a digital parenting platform that aims to give parents real-time data and insights to help parents feel more calm and confident. Its diversified portfolio of products includes Owlet Smart Sock, the first baby monitor to track an infant's oxygen levels, heart rate, and sleep trends; the Owlet Cam, which turns any smartphone into a baby monitor with high-definition clarity; the Owlet Monitor Duo, which offers the intelligence of the Owlet Smart Sock paired with the Owlet Cam; and Owlet Dream Lab, an interactive online program designed to be a parent's guide to building healthy sleep habits for their infants.
Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.